A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents

Mossaab Shuraih, Tomohiko Ai, Matteo Vatta, Yoshiro Sohma, Eileen M. Merkle, Erica Taylor, Zhaohui Li, Yutao Xi, Mehdi Razavi, Jeffrey A. Towbin, Jie Cheng

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Pharmacological Modification by SCN5A Polymorphism. Background: The potential pathophysiological role of common SCN5A polymorphisms in cardiac arrhythmias has been increasingly recognized. However, little is known about the impact of those polymorphisms on the pharmocological response of hNav1.5 to various antiarrhythmic agents. Methods and Results: The known SCN5A polymorphism, S524Y, was studied in comparison with the wild type (WT) define the SCN5A-Q1077del variant. The ion channel gating kinetics and pharmacology were evaluated using whole-cell patch-clamp methods in HEK-293 cells. Consistent with a previous report, the basal ion channel gating kinetics of S524Y were indistinguishable from the WT. Quinidine (20 μM) caused similar extent of tonic block reduction of sodium currents at -120 mV in WT and S524Y. Surprisingly, quinidine (20 μM) exerted a more use-dependent block by a 10 Hz pulse train in S524Y than in WT at 22°C (Ki: WT, 51.3 μM; S524Y, 20.3 μM). S524Y significantly delayed recovery from the use-dependent block, compared with the WT (τ = 88.6 ± 7.9 s vs 41.9 ± 6.6 s, P <0.005). Under more physiological conditions using a 2 Hz pulse train at 37°C, S524Y similarly enhanced the use-dependent block by quinidine. In addition, S524Y enhanced the use-dependent block by flecainide (12.5 μM), but not by mexiletine (100 μM). Conclusion: A common SCN5A polymorphism, S524Y, can enhance a use-dependent block by class Ia and Ic antiarrhythmic agents. Our findings may have clinical implications in pharmacological management of cardiac arrhythmias since this common SCN5A polymorphism might be a contributing factor to the variable antiarrhythmic response.

Original languageEnglish (US)
Pages (from-to)434-440
Number of pages7
JournalJournal of Cardiovascular Electrophysiology
Volume18
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Quinidine
Sodium Channels
Ion Channel Gating
Pharmacology
Cardiac Arrhythmias
Mexiletine
Flecainide
HEK293 Cells
Sodium
3-chloro-4,4-dimethyl-2-oxazolidinone

Keywords

  • Patch-clamp
  • Pharmacology
  • Polymorphism
  • SCN5A
  • Sodium channel

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents. / Shuraih, Mossaab; Ai, Tomohiko; Vatta, Matteo; Sohma, Yoshiro; Merkle, Eileen M.; Taylor, Erica; Li, Zhaohui; Xi, Yutao; Razavi, Mehdi; Towbin, Jeffrey A.; Cheng, Jie.

In: Journal of Cardiovascular Electrophysiology, Vol. 18, No. 4, 04.2007, p. 434-440.

Research output: Contribution to journalArticle

Shuraih, M, Ai, T, Vatta, M, Sohma, Y, Merkle, EM, Taylor, E, Li, Z, Xi, Y, Razavi, M, Towbin, JA & Cheng, J 2007, 'A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents', Journal of Cardiovascular Electrophysiology, vol. 18, no. 4, pp. 434-440. https://doi.org/10.1111/j.1540-8167.2007.00777.x
Shuraih, Mossaab ; Ai, Tomohiko ; Vatta, Matteo ; Sohma, Yoshiro ; Merkle, Eileen M. ; Taylor, Erica ; Li, Zhaohui ; Xi, Yutao ; Razavi, Mehdi ; Towbin, Jeffrey A. ; Cheng, Jie. / A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents. In: Journal of Cardiovascular Electrophysiology. 2007 ; Vol. 18, No. 4. pp. 434-440.
@article{080c1e5155264a8d9f94c64519cc1c01,
title = "A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents",
abstract = "Pharmacological Modification by SCN5A Polymorphism. Background: The potential pathophysiological role of common SCN5A polymorphisms in cardiac arrhythmias has been increasingly recognized. However, little is known about the impact of those polymorphisms on the pharmocological response of hNav1.5 to various antiarrhythmic agents. Methods and Results: The known SCN5A polymorphism, S524Y, was studied in comparison with the wild type (WT) define the SCN5A-Q1077del variant. The ion channel gating kinetics and pharmacology were evaluated using whole-cell patch-clamp methods in HEK-293 cells. Consistent with a previous report, the basal ion channel gating kinetics of S524Y were indistinguishable from the WT. Quinidine (20 μM) caused similar extent of tonic block reduction of sodium currents at -120 mV in WT and S524Y. Surprisingly, quinidine (20 μM) exerted a more use-dependent block by a 10 Hz pulse train in S524Y than in WT at 22°C (Ki: WT, 51.3 μM; S524Y, 20.3 μM). S524Y significantly delayed recovery from the use-dependent block, compared with the WT (τ = 88.6 ± 7.9 s vs 41.9 ± 6.6 s, P <0.005). Under more physiological conditions using a 2 Hz pulse train at 37°C, S524Y similarly enhanced the use-dependent block by quinidine. In addition, S524Y enhanced the use-dependent block by flecainide (12.5 μM), but not by mexiletine (100 μM). Conclusion: A common SCN5A polymorphism, S524Y, can enhance a use-dependent block by class Ia and Ic antiarrhythmic agents. Our findings may have clinical implications in pharmacological management of cardiac arrhythmias since this common SCN5A polymorphism might be a contributing factor to the variable antiarrhythmic response.",
keywords = "Patch-clamp, Pharmacology, Polymorphism, SCN5A, Sodium channel",
author = "Mossaab Shuraih and Tomohiko Ai and Matteo Vatta and Yoshiro Sohma and Merkle, {Eileen M.} and Erica Taylor and Zhaohui Li and Yutao Xi and Mehdi Razavi and Towbin, {Jeffrey A.} and Jie Cheng",
year = "2007",
month = "4",
doi = "10.1111/j.1540-8167.2007.00777.x",
language = "English (US)",
volume = "18",
pages = "434--440",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents

AU - Shuraih, Mossaab

AU - Ai, Tomohiko

AU - Vatta, Matteo

AU - Sohma, Yoshiro

AU - Merkle, Eileen M.

AU - Taylor, Erica

AU - Li, Zhaohui

AU - Xi, Yutao

AU - Razavi, Mehdi

AU - Towbin, Jeffrey A.

AU - Cheng, Jie

PY - 2007/4

Y1 - 2007/4

N2 - Pharmacological Modification by SCN5A Polymorphism. Background: The potential pathophysiological role of common SCN5A polymorphisms in cardiac arrhythmias has been increasingly recognized. However, little is known about the impact of those polymorphisms on the pharmocological response of hNav1.5 to various antiarrhythmic agents. Methods and Results: The known SCN5A polymorphism, S524Y, was studied in comparison with the wild type (WT) define the SCN5A-Q1077del variant. The ion channel gating kinetics and pharmacology were evaluated using whole-cell patch-clamp methods in HEK-293 cells. Consistent with a previous report, the basal ion channel gating kinetics of S524Y were indistinguishable from the WT. Quinidine (20 μM) caused similar extent of tonic block reduction of sodium currents at -120 mV in WT and S524Y. Surprisingly, quinidine (20 μM) exerted a more use-dependent block by a 10 Hz pulse train in S524Y than in WT at 22°C (Ki: WT, 51.3 μM; S524Y, 20.3 μM). S524Y significantly delayed recovery from the use-dependent block, compared with the WT (τ = 88.6 ± 7.9 s vs 41.9 ± 6.6 s, P <0.005). Under more physiological conditions using a 2 Hz pulse train at 37°C, S524Y similarly enhanced the use-dependent block by quinidine. In addition, S524Y enhanced the use-dependent block by flecainide (12.5 μM), but not by mexiletine (100 μM). Conclusion: A common SCN5A polymorphism, S524Y, can enhance a use-dependent block by class Ia and Ic antiarrhythmic agents. Our findings may have clinical implications in pharmacological management of cardiac arrhythmias since this common SCN5A polymorphism might be a contributing factor to the variable antiarrhythmic response.

AB - Pharmacological Modification by SCN5A Polymorphism. Background: The potential pathophysiological role of common SCN5A polymorphisms in cardiac arrhythmias has been increasingly recognized. However, little is known about the impact of those polymorphisms on the pharmocological response of hNav1.5 to various antiarrhythmic agents. Methods and Results: The known SCN5A polymorphism, S524Y, was studied in comparison with the wild type (WT) define the SCN5A-Q1077del variant. The ion channel gating kinetics and pharmacology were evaluated using whole-cell patch-clamp methods in HEK-293 cells. Consistent with a previous report, the basal ion channel gating kinetics of S524Y were indistinguishable from the WT. Quinidine (20 μM) caused similar extent of tonic block reduction of sodium currents at -120 mV in WT and S524Y. Surprisingly, quinidine (20 μM) exerted a more use-dependent block by a 10 Hz pulse train in S524Y than in WT at 22°C (Ki: WT, 51.3 μM; S524Y, 20.3 μM). S524Y significantly delayed recovery from the use-dependent block, compared with the WT (τ = 88.6 ± 7.9 s vs 41.9 ± 6.6 s, P <0.005). Under more physiological conditions using a 2 Hz pulse train at 37°C, S524Y similarly enhanced the use-dependent block by quinidine. In addition, S524Y enhanced the use-dependent block by flecainide (12.5 μM), but not by mexiletine (100 μM). Conclusion: A common SCN5A polymorphism, S524Y, can enhance a use-dependent block by class Ia and Ic antiarrhythmic agents. Our findings may have clinical implications in pharmacological management of cardiac arrhythmias since this common SCN5A polymorphism might be a contributing factor to the variable antiarrhythmic response.

KW - Patch-clamp

KW - Pharmacology

KW - Polymorphism

KW - SCN5A

KW - Sodium channel

UR - http://www.scopus.com/inward/record.url?scp=33947259522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947259522&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8167.2007.00777.x

DO - 10.1111/j.1540-8167.2007.00777.x

M3 - Article

C2 - 17331104

AN - SCOPUS:33947259522

VL - 18

SP - 434

EP - 440

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 4

ER -